Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 6/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | PANK3 | Q9H999 | 4/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249325 | 0.84 | HRH3 (0.48) | OGAHRH3TRPV1PANK3KDM4E | |
| SCHEMBL20038121 | 0.80 | OGA (0.52) | OGASCN9AHRH3PANK3TLR9 | |
| SCHEMBL20249352 | 0.80 | TRPV1 (0.39) | OGAHRH3TRPV1GPR119KDM4E | |
| SCHEMBL20249349 | 0.78 | DRD2 (0.43) | OGATRPV1PANK3 | |
| SCHEMBL20249387 | 0.78 | OGA (0.42) | OGAHRH3TRPV1PANK3SLC6A9 | |
| SCHEMBL20249320 | 0.77 | OGA (0.39) | OGATRPV1PANK3TLR9TLR8 | |
| SCHEMBL20249151 | 0.77 | GAA (0.47) | TRPV1KDM4E | |
| SCHEMBL20249268 | 0.76 | HRH4 (0.51) | HRH3KDM4E | |
| SCHEMBL20249439 | 0.75 | TRPV1 (0.49) | TRPV1PANK3GPR119SLC6A9 | |
| SCHEMBL20249362 | 0.75 | TRPV1 (0.46) | TRPV1PANK3GPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | OGA 4627/4885SCN9A 3308/4885HRH3 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.